Keel Point’s Neurocrine Biosciences NBIX Stock Holding History

Keel Point’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,732	Closed	-$236K	–	482
2024 Q4	$236K	Buy	+1,732	New	+$214K	0.02%	377

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Keel Point's NBIX Position: Q1 2025 in Review

Keel Point sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 1,732 shares — an estimated $236K sold.

Keel Point first reported a position in NBIX in Q4 2024 and held it in 1 quarter. The position peaked at $236K in Q4 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

Keel Point reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
Keel Point sold 1,732 Neurocrine Biosciences shares in Q1 2025, an estimated $236K.
Keel Point first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 1 quarter.
Keel Point's Neurocrine Biosciences position peaked at $236K in Q4 2024.
586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Keel Point's 13F filing for Q1 2025, filed 15 May 2025.